FindTrial
Sign In

Effect of Herbal Medicine in the treatment of chronic bronchitis

EFFICACY OF NIRGUNDI GHRITA WITH AND WITHOUT PIPPALI RASAYANA IN THE MANAGEMENT OF KAPHAJA KASA W.S.R. TO CHRONIC BRONCHITIS-AN OPEN LABELLED, COMPARATIVE RANDOMIZED CLINICAL TRIAL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027746
Enrollment
30
Registered
2020-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J980- Diseases of bronchus, not elsewhere classified

Interventions

Intervention1: Group-A: Nirgundi Ghrtita Group-B: Nirgundi Ghrtita with Pippali Rasayana : Group-A: Nirgundi Ghrtita 20 ml Orally with Warm Water on empty stomach. Group-B: Nirgundi Ghrtita 20 ml Oral

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda Gujarat Ayurved University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Symptoms of chronic bronchitis such as cough for at least 3 months from last 2 2.successive years sputum production shortness of breath wheezing which may be associated with symptoms such as fatigue sore throat nasal congestion headache or chest discomfort 3.Uncomplicated chronic bronchitis & those who willing to participate in the study for 8 weeks

Exclusion criteria

Exclusion criteria: 1. Age of Patients below 18 years and above 60 Years. 2. Patients suffering from acute bronchitis having Peak expiratory flow rate (PEFR) 3. Patients with poorly controlled diabetes mellitus (HemoglobinA1c > 10%) and poorly controlled hypertension ( >160/100 mm of Hg), patients on prolonged ( >6 weeks) medication with corticosteroids, bronchodilators, mast cell stabilizers, antidepressants, anticholinergics or other drugs that may have an influence on the outcome of the study. 4. Patients suffering from major systemic illness necessitating long term drug treatment (rheumatoid arthritis, tuberculosis, psycho-neuro-endocrinal disorders, etc.) and patients with clinical evidence of heart failure

Design outcomes

Primary

MeasureTime frame
PRIMARY OUTCOME:The trial drugs will help in relieving signs and symptoms of chronic bronchitis and thus will effective in the management of it.Timepoint: after 8 weeks—

Secondary

MeasureTime frame
ï?¶SECONDARY OUTCOME: The drug will improve the quality of life and thus will act as disease modifying after for Kaphaja Kasa. Timepoint: after 16 weeks—

Countries

India

Contacts

Public ContactDR MANDIP GOYAL

IPGT and RA JAMNAGAR

kaurmandip22@yahoo.com9427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026